165P Efficacy and safety of tislelizumab (TIS) plus lenvatinib (LEN) as first-line treatment in patients (pts) with unresectable hepatocellular carcinoma (uHCC): A single-arm, multicenter, phase II trial. (December 2022) - Xu, L.; Chen, J.; Yang, J.; Gong, W.; Zhang, Y.; Zhao, H.; Yan, S.; Jia, W.; Wu, Z.; Liu, C.; Song, X.; Ma, Y.; et al.